These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 26583516)

  • 1. Medians and Milestones in Describing the Path to Cancer Cures: Telling "Tails".
    Hellmann MD; Kris MG; Rudin CM
    JAMA Oncol; 2016 Feb; 2(2):167-8. PubMed ID: 26583516
    [No Abstract]   [Full Text] [Related]  

  • 2. Mixed response and time-to-event endpoints for multistage single-arm phase II design.
    Lai X; Zee BC
    Trials; 2015 Jun; 16():250. PubMed ID: 26037094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nine-year change in statistical design, profile, and success rates of Phase II oncology trials.
    Ivanova A; Paul B; Marchenko O; Song G; Patel N; Moschos SJ
    J Biopharm Stat; 2016; 26(1):141-9. PubMed ID: 26368744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval.
    Sobrero A; Bruzzi P
    J Clin Oncol; 2009 Dec; 27(35):5868-73. PubMed ID: 19826122
    [No Abstract]   [Full Text] [Related]  

  • 5. Multiplicity in confirmatory clinical trials: a case study with discussion from a JSM panel.
    Wang SJ; Bretz F; Dmitrienko A; Hsu J; Hung HM; Koch G; Maurer W; Offen W; O'Neill R
    Stat Med; 2015 Nov; 34(26):3461-80. PubMed ID: 26112381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response Rate as an Approval End Point in Oncology: Back to the Future.
    Blumenthal GM; Pazdur R
    JAMA Oncol; 2016 Jun; 2(6):780-1. PubMed ID: 26913938
    [No Abstract]   [Full Text] [Related]  

  • 7. N-of-1 trials in oncology.
    Collette L; Tombal B
    Lancet Oncol; 2015 Aug; 16(8):885-6. PubMed ID: 26248830
    [No Abstract]   [Full Text] [Related]  

  • 8. Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
    Ben-Aharon O; Magnezi R; Leshno M; Goldstein DA
    Oncologist; 2019 Nov; 24(11):1469-1478. PubMed ID: 31320502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overall survival: patient outcome, therapeutic objective, clinical trial end point, or public health measure?
    Saad ED; Buyse M
    J Clin Oncol; 2012 May; 30(15):1750-4. PubMed ID: 22393092
    [No Abstract]   [Full Text] [Related]  

  • 10. Joint modeling of clinical efficacy and safety with an application to diabetes studies.
    Zhao Y; Shen W; Fu H
    J Biopharm Stat; 2013; 23(5):1155-71. PubMed ID: 23957521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ODAC chronicles--part 2. Statistics and clinical medicine in the USA: the triumph of science over art?
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):941-4. PubMed ID: 15606323
    [No Abstract]   [Full Text] [Related]  

  • 12. Cancer concepts and principles: primer for the interventional oncologist-part I.
    Hickey R; Vouche M; Sze DY; Hohlastos E; Collins J; Schirmang T; Memon K; Ryu RK; Sato K; Chen R; Gupta R; Resnick S; Carr J; Chrisman HB; Nemcek AA; Vogelzang RL; Lewandowski RJ; Salem R
    J Vasc Interv Radiol; 2013 Aug; 24(8):1157-64. PubMed ID: 23809510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of adaptive designs for single-armed phase II oncology trials.
    Kieser M; Englert S
    J Biopharm Stat; 2015; 25(3):602-15. PubMed ID: 24905363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of nonrandomized trials in the evaluation of oncology drugs.
    Simon R; Blumenthal GM; Rothenberg ML; Sommer J; Roberts SA; Armstrong DK; LaVange LM; Pazdur R
    Clin Pharmacol Ther; 2015 May; 97(5):502-7. PubMed ID: 25676488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statistics in oncology.
    Land SR; Abrams J; Buyse M; Chappell RJ
    J Clin Oncol; 2008 Aug; 26(22):3668. PubMed ID: 18669450
    [No Abstract]   [Full Text] [Related]  

  • 16. Strategies for power calculations in predictive biomarker studies in survival data.
    Chen DT; Huang PY; Lin HY; Haura EB; Antonia SJ; Cress WD; Gray JE
    Oncotarget; 2016 Dec; 7(49):80373-80381. PubMed ID: 27661007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?
    Rubinstein LV; Dancey JE; Korn EL; Smith MA; Wright JJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1422-3. PubMed ID: 17895470
    [No Abstract]   [Full Text] [Related]  

  • 18. Prescribing patterns of surgical oncologists: are we surgeons, oncologists, or both? Results of a society of surgical oncology survey.
    Balch CM
    Ann Surg Oncol; 2007 Oct; 14(10):2685-6. PubMed ID: 17786520
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug development in oncology: a regulatory perspective.
    Augustus S
    Am J Ther; 2011 Jul; 18(4):323-31. PubMed ID: 20335790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug Development, Trial Design, and Endpoints in Oncology: Adapting to Rapidly Changing Science.
    Blumenthal GM; Goldberg KB; Pazdur R
    Clin Pharmacol Ther; 2017 May; 101(5):572-574. PubMed ID: 28074476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.